TRAX Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
32.8M
-6.0%
34.9M
R&D
23.8M
-7.0%
25.6M
SG&A
9.0M
-3.2%
9.3M
Operating Income
-32844000
+6.0%
-34937000
EBITDA
-32752000
+6.0%
-34832000
Net Income
-31356000
+6.0%
-33374000
EPS (Basic)
$-0.88
+7.4%
$-0.95
EPS (Diluted)
$-0.88
+7.4%
$-0.95
Shares (Diluted)
35.7M
+2.1%
35.0M
First Tracks Biotherapeutics (TRAX) — Financials